Meridian Bioscience buys Bioline
This article was originally published in The Gray Sheet
Executive Summary
Diagnostics firm Meridian Bioscience acquired molecular biology reagent-maker Bioline for $23.3 million in cash on July 20. London-based Bioline, with anticipated 2010 sales of $12 million, is a profitable, large-volume producer of nucleotides, DNA polymerase enzymes, and other core reagents for molecular biology, Meridian explains. The components are used in polymerase chain reaction testing. Bioline will "complement Meridian's expanding life science product lines sold into the research, pharmaceutical, and commercial diagnostic markets," the company said